Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anlon HealthcareNSE:AHCL -1.25%20 EV-to-EBITDA is 0.55 as of Aug. 13, 2026, which is 95% below its 10-year median of 11.09. GuruFocus rates NSE:AHCL with a GF Score™ of 20/100. The stock has 4 warning signs investors should review. Among 734 Drug Manufacturers companies, Anlon Healthcare ranks better than 97.41% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Anlon Healthcare's enterprise value is ₹8,202 Mil.
Anlon Healthcare's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ₹14,871 Mil. Therefore, Anlon Healthcare's EV-to-EBITDA for today is 0.55.
The historical rank and industry rank for Anlon Healthcare's EV-to-EBITDA or its related term are showing as below:
NSE:AHCL'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 0.39 Med: 11.09 Max: 23.58
Current: 0.55
During the past 5 years, the highest EV-to-EBITDA of Anlon Healthcare was 23.58. The lowest was 0.39. And the median was 11.09.
NSE:AHCL's EV-to-EBITDA is ranked better than 97.41% of 734
companies
in the Drug Manufacturers industry
Industry Median: 13.33
vs NSE:AHCL: 0.55
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Anlon Healthcare's PE Ratio (TTM) for today is calculated as:
Anlon Healthcare's share price for today is ₹14.23.
Anlon Healthcare's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.681.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Anlon Healthcare's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Anlon Healthcare's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anlon Healthcare EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anlon Healthcare's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Anlon Healthcare's EV-to-EBITDA falls into.
Anlon Healthcare's current Enterprise Value is ₹8,202 Mil.
Anlon Healthcare's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹14,871 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anlon Healthcare (NSE:AHCL) has a EV-to-EBITDA of 0.55 as of Aug. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Anlon Healthcare. This is 95% below median its historical median of 11.09. Over the past decade, Anlon Healthcare's EV-to-EBITDA has ranged from 0.39 to 23.58. According to the industry distribution chart, Anlon Healthcare ranks #19 out of 734 companies in the Drug Manufacturers industry, placing it in the top 2.6%.
Is Anlon Healthcare's EV-to-EBITDA too high?
Anlon Healthcare's current EV-to-EBITDA of 0.55 is 95% below median its 10-year median of 11.09. Over the past 10 years, this metric has ranged from a low of 0.39 to a high of 23.58. The Drug Manufacturers industry median EV-to-EBITDA is 13.33. Anlon Healthcare's value of 0.55 is 95.9% below this industry median. Based on the distribution chart, Anlon Healthcare ranks #19 out of 734 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Anlon Healthcare has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Anlon Healthcare's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Anlon Healthcare ranks #19 out of 734 companies for EV-to-EBITDA. This places Anlon Healthcare in the top 3% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.33. Anlon Healthcare's value of 0.55 is 95.9% below this benchmark. Historically, Anlon Healthcare's own EV-to-EBITDA has ranged from 0.39 to 23.58 over the past decade. While the company's 10-year median is 11.09 vs. the industry median of 13.33, Anlon Healthcare has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.33, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anlon Healthcare's current EV-to-EBITDA of 0.55 is 95.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Anlon Healthcare. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anlon Healthcare's current EV-to-EBITDA is 0.55, which is 95% below median its own 10-year median of 11.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anlon Healthcare stock overvalued right now?
Anlon Healthcare (NSE:AHCL) has a current EV-to-EBITDA of 0.55. The current EV-to-EBITDA is 0.55, which is 95% below median its 10-year median of 11.09 and 95.9% below the Drug Manufacturers industry median of 13.33. Anlon Healthcare's overall GF Score™ is 20/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Anlon Healthcare (NSE:AHCL), the current EV-to-EBITDA is 0.55 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anlon Healthcare Ltd is a chemical manufacturing company engaged in manufacturing of; (i) high purity advance pharmaceutical intermediates which serves as raw material/ key starting material in the manufacturing of active pharmaceutical ingredients; and (ii) active pharmaceutical ingredients which serves as a raw material for pharmaceutical formulations in preparation of various type of Finished Dosage Formula such as tablet, capsules, ointment, syrup etc, ingredients in nutraceuticals formulations, personal care products and animal health products. Its products spans across the family of pharmaceutical intermediates, active pharmaceutical ingredients, nutraceutical APIs and ingredients for personal care and veterinary API.
20GF Score
Get the complete analysis for NSE:AHCL
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AHCL has been successfully added to your 
